945 related articles for article (PubMed ID: 15530555)
1. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
2. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to human tumors: development of tumor vaccines.
Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
[TBL] [Abstract][Full Text] [Related]
4. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
5. Links between innate and cognate tumor immunity.
Ghiringhelli F; Apetoh L; Housseau F; Kroemer G; Zitvogel L
Curr Opin Immunol; 2007 Apr; 19(2):224-31. PubMed ID: 17303400
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
7. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
Ahmad M; Rees RC; Ali SA
Cancer Immunol Immunother; 2004 Oct; 53(10):844-54. PubMed ID: 15197495
[TBL] [Abstract][Full Text] [Related]
8. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
9. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
10. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
11. Suppressive influences in the immune response to cancer.
Bronte V; Mocellin S
J Immunother; 2009 Jan; 32(1):1-11. PubMed ID: 19307988
[TBL] [Abstract][Full Text] [Related]
12. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
13. The Janus face of dendritic cells in cancer.
Chaput N; Conforti R; Viaud S; Spatz A; Zitvogel L
Oncogene; 2008 Oct; 27(45):5920-31. PubMed ID: 18836473
[TBL] [Abstract][Full Text] [Related]
14. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
15. Tumor escape from immune surveillance.
Costello RT; Gastaut JA; Olive D
Arch Immunol Ther Exp (Warsz); 1999; 47(2):83-8. PubMed ID: 10202560
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth.
Lin A; Schildknecht A; Nguyen LT; Ohashi PS
Immunol Lett; 2010 Jan; 127(2):77-84. PubMed ID: 19778555
[TBL] [Abstract][Full Text] [Related]
17. Capitalizing on the immunogenicity of dying tumor cells.
Fonseca C; Dranoff G
Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
[TBL] [Abstract][Full Text] [Related]
18. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
[TBL] [Abstract][Full Text] [Related]
19. Regulatory balance between the immune response of tumor antigen-specific T-cell receptor gene-transduced CD8 T cells and the suppressive effects of tolerogenic dendritic cells.
Fujii S; Nishimura MI; Lotze MT
Cancer Sci; 2005 Dec; 96(12):897-902. PubMed ID: 16367910
[TBL] [Abstract][Full Text] [Related]
20. Tumors and the danger model.
Kowalczyk DW
Acta Biochim Pol; 2002; 49(2):295-302. PubMed ID: 12362970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
